Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 7
2003 8
2004 10
2005 25
2006 46
2007 34
2008 33
2009 33
2010 43
2011 35
2012 43
2013 41
2014 54
2015 56
2016 63
2017 55
2018 47
2019 66
2020 73
2021 89
2022 113
2023 100
2024 65

Text availability

Article attribute

Article type

Publication date

Search Results

1,018 results

Results by year

Filters applied: . Clear all
Page 1
Histone Lactylation Boosts Reparative Gene Activation Post-Myocardial Infarction.
Wang N, Wang W, Wang X, Mang G, Chen J, Yan X, Tong Z, Yang Q, Wang M, Chen L, Sun P, Yang Y, Cui J, Yang M, Zhang Y, Wang D, Wu J, Zhang M, Yu B. Wang N, et al. Among authors: sun p. Circ Res. 2022 Nov 11;131(11):893-908. doi: 10.1161/CIRCRESAHA.122.320488. Epub 2022 Oct 21. Circ Res. 2022. PMID: 36268709 Free article.
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma.
Fang H, Sun Q, Zhou J, Zhang H, Song Q, Zhang H, Yu G, Guo Y, Huang C, Mou Y, Jia C, Song Y, Liu A, Song K, Lu C, Tian R, Wei S, Yang D, Chen Y, Li T, Wang K, Yu Y, Lv Y, Mo K, Sun P, Yu X, Song X. Fang H, et al. Among authors: sun p. Mol Cancer. 2023 Jun 23;22(1):99. doi: 10.1186/s12943-023-01791-1. Mol Cancer. 2023. PMID: 37353784 Free PMC article.
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.
Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, Fang J, Chen G, Zhang Z, Lv D, Jiang L, Wu R, Jin X, Zhang X, Zhang J, Xie C, Sun G, Huang D, Cui J, Guo R, Han Z, Chen Z, Liang J, Zhuang W, Hu X, Zang A, Zhang Y, Cang S, Lan Y, Chen X, Liu L, Li X, Chen J, Ma R, Guo Y, Sun P, Tian P, Pan Y, Liu Z, Cao P, Ding L, Wang Y, Yuan X, Wu P. Lu S, et al. Among authors: sun p. Lancet Respir Med. 2023 Oct;11(10):905-915. doi: 10.1016/S2213-2600(23)00183-2. Epub 2023 May 24. Lancet Respir Med. 2023. PMID: 37244266 Clinical Trial.
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Cui J, Li Y, Zhao H, Fang J, Xue J, Hu C, Sun P, Du Y, Zhou H, Wang S, Zhang W. Zhou C, et al. Among authors: sun p. J Thorac Oncol. 2021 Sep;16(9):1501-1511. doi: 10.1016/j.jtho.2021.04.011. Epub 2021 May 25. J Thorac Oncol. 2021. PMID: 34048947 Free article. Clinical Trial.
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Wang J, Chen R, Qin M, Wang H, Yang J. Zhou C, et al. Among authors: sun p. Nat Cancer. 2023 Jun;4(6):860-871. doi: 10.1038/s43018-023-00578-z. Epub 2023 Jun 15. Nat Cancer. 2023. PMID: 37322367 Clinical Trial.
Time to abandon CAR-T monotherapy for solid tumors.
Yin L, Wan Z, Sun P, Shuai P, Liu Y. Yin L, et al. Among authors: sun p. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188930. doi: 10.1016/j.bbcan.2023.188930. Epub 2023 Jun 5. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37286147 Review.
1,018 results